ResearcherUniversity of ArizonaNo recent work listed
Mahdi Gharaibeh
Matched on ORCID iD 0000-0003-2417-2862; OpenAlex author ID A5065651999. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 2
2017: 1 paper · 2018: 2 papers
Papers 3
- Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. Co-author DOI 10.1007/s40273-018-0678-6↗
- Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. Co-author DOI 10.1007/s40273-018-0684-8↗
- Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review. Co-author DOI 10.1007/s40273-016-0452-6↗
Closest collaborators
The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Ali McBride · 3 shared papers, 2017–2018 · strength 0.27
- Paper Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review. DOI 10.1007/s40273-016-0452-6↗
- Paper Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. DOI 10.1007/s40273-018-0678-6↗
- Paper Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. DOI 10.1007/s40273-018-0684-8↗
- Ivo L Abraham · 2 shared papers, 2018 · strength 0.17
- Paper Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. DOI 10.1007/s40273-018-0678-6↗
- Paper Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. DOI 10.1007/s40273-018-0684-8↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.